Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Biomarin Pharmaceutical
BMRN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$70.84
-0.57
-0.80%
Last update: 1:09 PM
15 minutes delayed
Get Report
Comment
Biomarin Pharmaceutical (BMRN) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Biomarin Pharmaceutical (NASDAQ:BMRN) Stock
Biomarin Pharmaceutical Stock (NASDAQ: BMRN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, September 18, 2024
BioMarin To Present Positive VOXZOGO (Vosorit...
Benzinga Newsdesk
Tuesday, September 17, 2024
Scotiabank Maintains Sector Perform on Biomar...
Benzinga Newsdesk
Truist Securities Maintains Buy on Biomarin P...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Biomarin ...
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on Bioma...
Benzinga Newsdesk
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
B of A Securities Maintains Buy on Biomarin P...
Benzinga Newsdesk
Stifel Maintains Buy on Biomarin Pharmaceutic...
Benzinga Newsdesk
Bernstein Maintains Outperform on Biomarin Ph...
Benzinga Newsdesk
Monday, September 16, 2024
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Vandana Singh
BioMarin Pharmaceutical shares are trading lo...
Benzinga Newsdesk
Friday, September 13, 2024
Canaccord Genuity Maintains Hold on Biomarin ...
Benzinga Newsdesk
Tuesday, September 10, 2024
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Benzinga Insights
Monday, September 09, 2024
Cantor Fitzgerald Reiterates Overweight on Bi...
Benzinga Newsdesk
Friday, September 06, 2024
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Vandana Singh
Thursday, September 05, 2024
BioMarin Pharmaceuticals shares are trading l...
Benzinga Newsdesk
JP Morgan Maintains Overweight on Biomarin Ph...
Benzinga Newsdesk
RBC Capital Reiterates Sector Perform on Biom...
Benzinga Newsdesk
Scotiabank Maintains Sector Perform on Biomar...
Benzinga Newsdesk
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
Vandana Singh
Piper Sandler Maintains Overweight on Biomari...
Benzinga Newsdesk
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Benzinga Insights
Truist Securities Maintains Buy on Biomarin P...
Benzinga Newsdesk
Wednesday, September 04, 2024
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Vandana Singh
BioMarin Pharmaceutical Shares Resume Trade
Benzinga Newsdesk
Trading Halt: Halt status updated at 1:25:00 ...
Benzinga Newsdesk
From BioMarin Investor Day, Co Provides New C...
Benzinga Newsdesk
BioMarin Pharmaceutical Says Co Will Be Entit...
Benzinga Newsdesk
BioMarin Pharmaceutical Says On Aug 28, Enter...
Benzinga Newsdesk
Trading Halt: Halted at 10:30:00 a.m. ET - Tr...
Benzinga Newsdesk
Wednesday, August 28, 2024
BioMarin Plans To Reduce Its Global Workforce...
Benzinga Newsdesk
Tuesday, August 27, 2024
Piper Sandler Maintains Overweight on Biomari...
Benzinga Newsdesk
Wednesday, August 21, 2024
Stifel Maintains Buy on Biomarin Pharmaceutic...
Benzinga Newsdesk
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Benzinga Insights
Tuesday, August 20, 2024
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Benzinga Insights
BioMarin Pharmaceutical shares are trading hi...
Benzinga Newsdesk
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
Bernstein Upgrades Biomarin Pharmaceutical to...
Benzinga Newsdesk
Wednesday, August 07, 2024
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Tuesday, August 06, 2024
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
Vandana Singh
TD Cowen Maintains Buy on Biomarin Pharmaceut...
Benzinga Newsdesk
Scotiabank Maintains Sector Perform on Biomar...
Benzinga Newsdesk
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
BioMarin Pharmaceutical shares are trading hi...
Benzinga Newsdesk
RBC Capital Reiterates Sector Perform on Biom...
Benzinga Newsdesk
Barclays Maintains Overweight on Biomarin Pha...
Benzinga Newsdesk
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Avi Kapoor
Evercore ISI Group Maintains Outperform on Bi...
Benzinga Newsdesk
Stifel Maintains Buy on Biomarin Pharmaceutic...
Benzinga Newsdesk
Monday, August 05, 2024
BioMarin Pharmaceutical shares are trading hi...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch